Nanobiotix S.A. American Depositary Shares (5NRA)
XMUN 
Summary
Nanobiotix: A Highly Speculative Bet On A Potential Radiotherapy Platform
Nanobiotix is rated a strong speculative Buy, driven by risk-adjusted upside from its JNJ-1900 radioenhancer platform in partnership with Janssen. NBTX's lead indication, head and neck cancer, offers a modeled $624M valuation, but lung cancer programs—despite higher risk—represent two-thirds of the $4.5B risk-adjusted opportunity. JNJ-1900's platform potential is vast, with even low-probability broad adoption scenarios materially boosting valuation; upcoming clinical milestones in 2026–2027 are pivotal.
Nanobiotix: A Royalty-Backed Physics Platform Hidden Inside A Biotech
Nanobiotix is evolving into a capital-light, milestone- and royalty-driven oncology platform with JNJ-1900 at its core. JNJ-1900, now led by Johnson & Johnson, targets radioenhancement across multiple solid tumors, with a $2.6B potential milestone structure and double-digit royalties. Recent financing and a May 2026 equity raise extend NBTX's cash runway through 2029, shifting clinical and operational risk to J&J.
Nanobiotix S.A. (NBTX) Q4 2025 Earnings Call Transcript
Nanobiotix S.A. (NBTX) Q4 2025 Earnings Call Transcript
Nanobiotix S.A. American Depositary Shares (5NRA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Nanobiotix S.A. American Depositary Shares ever had a stock split?
Nanobiotix S.A. American Depositary Shares Profile
| Biotechnology Industry | Healthcare Sector | Laurent Levy CEO | XMUN Exchange | US63009J1079 ISIN |
| FR Country | 100 Employees | - Last Dividend | - Last Split | 11 Dec 2020 IPO Date |
Overview
Nanobiotix S.A. represents a pioneering position in the biotechnological realm, focusing on the advancement of novel therapeutic options for cancer treatment alongside addressing various other medical necessities that are yet to meet satisfying solutions. Established in the year 2003, the company has carved its niche in the clinical-stage biotechnology sector, dedicating its extensive research and development efforts towards creating innovative product candidates. With its headquarters stationed in Paris, France, Nanobiotix S.A. has expanded its strategic footprint by establishing a notable partnership with Lian Oncology Limited. This collaboration aims at accelerating the development and commercialization of its flagship product, NBTXR3, within vital Asian markets such as Greater China, South Korea, Singapore, and Thailand, thereby reflecting the company's commitment to global healthcare improvement and cancer care innovation.
Products and Services
Nanobiotix S.A.'s product development portfolio is spearheaded by its lead product candidate, NBTXR3, which underscores the company’s innovative approach towards cancer treatment:
- NBTXR3: A breakthrough in oncological therapy, NBTXR3 is a sterile aqueous suspension embracing crystalline hafnium oxide nanoparticles. This novel therapeutic agent is designed to target and treat a wide array of cancers, by enhancing the efficacy of radiotherapy, a cornerstone in cancer treatment modalities. Its versatility and effectiveness are highlighted across several cancer types, including:
- Soft Tissue Sarcoma – Utilizing the properties of NBTXR3 to improve tumor control and minimize damage to the surrounding healthy tissues.
- Head and Neck Cancers – Aiming to enhance the precision and impact of radiotherapy in these critically located tumors.
- Liver Cancers – Offering a potential adjunctive therapy that could improve outcomes in this hard-to-treat cancer type.
- Prostate Cancer, Pancreatic Cancer, Esophageal Cancer, Rectal Cancer, and Non-Small Cell Lung Cancer – Expanding the application of NBTXR3 to a broader spectrum of malignancies, where innovative treatments are direly needed.
This multifaceted approach to cancer treatment showcases Nanobiotix S.A.’s commitment to pushing the boundaries of medical science and providing new avenues for patients grappling with various forms of cancer.
